In supporting the investment of cell and gene therapy, Japan has been developing fast, especially in January 2019. Japanese government allowed the use of gene and a genetic test for the cancer drug and treatment to be covered by national public health insurance. The essential testing is cancer genome profiling that is of similar quality to the case of the European Union and the USA. These new tests will bring new hope to the patients who encounter unsuccessful treatment from conventional cancer treatment. There are two authorized test systems under the insurance coverage, National Cancer Center and health instrument-maker Sysmex Corp., and import technology from the USA by Chugai corp. Both tests can identify the cancerous gene for at least 101 points.